岗位职责:
1.Develop and establish preclinical in vivo models for Alzheimer’s disease (AD),Parkinson’s disease (PD), stroke, and pain-related CNS disorders to evaluate novel therapeutics.
2.Work closely with Medicinal Chemistry, Biologics Discovery, in vitro Pharmacology, DMPK, Toxicology teams to design and execute in vivo pharmacology studies, supporting target validation, pharmacokinetics (PK), and pharmacodynamics (PD).
3.Design and conduct behavioral, biochemical, and molecular assays in rodent models to assess drug efficacy, mechanism of action (MoA), and biomarker
responses.
4.Collaborate with cross-functional teams to develop in vivo proof-of-concept (PoC)studies, ensuring alignment with program milestones.
5.Serve as a subject matter expert in CNS disease model development, providing insights on experimental design, troubleshooting, and data interpretation.
6.Perform tissue collection and biomarker assessments using molecular, histological, and biochemical techniques (IHC, IF, qPCR, ELISA, MSD, Luminex, Western blot).
7.Mentor and manage junior scientists and research associates, providing scientific/technical guidance, performance feedback, and professional development.
8.Contribute to the evaluation of new drug targets, MoA studies, and proposal preparation for CNS drug discovery programs.
Support IND-enabling studies and participate in regulatory document preparation for clinical submission.
任职要求:
1.PhD(with at least 3 years of industry experience) in neuroscience, neuropharmacology, behavioral neuroscience, or related fields.
2.Hands-on experience in CNS in vivo pharmacology, with proven expertise in AD,PD, stroke, and pain models.
3.Proficiency in rodent handling, stereotaxic surgeries, behavioral assays, and drug administration (IV, IP, SC, ICV, IT, PO, etc.).
4.Extensive experience in ex vivo neuropharmacology techniques, including flow cytometry, ELISA, multiplex cytokine analysis, Western blot, and transcriptomics(RNA-seq, proteomics).
5.Proven track-record of supporting CNS projects into IND submission and familiar with China NMPA/the US FDAIND submission requirements for CNS in vivo pharmacology.
6.Strong ability in literature and patent research, analytical thinking, and problem-solving.
7.Excellent verbal and written communication skills in English(CET6/IELTS/TOEFL/GRE scores preferred).
8.Highly collaborative team player with strong interdisciplinary communication skills.
9.Key Expertise in Model Establishment and Experimental Techniques：
1)Alzheimer’s Disease (AD) Models
1.1 Transgenic models(e.g., APP/PS1, 5xFAD, Tauopathy models)
1.2 Aβ or tau injection models(ICV or stereotaxic injection)
1.3 Cognitive behavioral assays(e.g., Morris water maze, novel object recognition, Y-maze, fear conditioning, radial arm maze)
1.4 Neuroinflammation and glial activation assessment
2) Parkinson’s Disease (PD) Models
2.1 Neurotoxin-based models(e.g., MPTP, 6-OHDA lesion models)
2.2 α-synuclein preformed fibril (PFF) injection models
2.3 Behavioral tests for motor function(e.g., rotarod, pole test, open field, gait analysis)
2.4 Dopaminergic neuron degeneration analysis(e.g., TH staining, dopamine quantification)
3) Stroke Models
3.1 Middle Cerebral Artery Occlusion (MCAO) model including pMCAO, tMCAO and eMCAO models
3.2 Photothrombotic ischemia model
3.3 Neurological and motor function assessments(e.g., neurological deficit score, cylinder test, adhesive removal test)
3.4 Histological and molecular assessment of infarct size and neuroprotection
4) Pain-related CNS Disease Models
4.1 Neuropathic pain models(e.g., spinal nerve ligation (SNL), chronic constriction injury (CCI), chemotherapy-induced neuropathy)
4.2 Inflammatory pain models(e.g., CFA-induced paw inflammation, formalin test)
4.3 Pain sensitivity assessments(e.g., von Frey test, hot plate, Hargreaves test, mechanic alallodynia)